In one paragraphArticle in JNCI cancer spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Andres V Ardisson KoratUSDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, United States.ORCID 0000-0003-4599-2245 Emily L DeublerDepartment of Population Science, American Cancer Society, Atlanta, GA, United States.ORCID 0000-0003-4511-1452 Lauren R TerasDepartment of Population Science, American Cancer Society, Atlanta, GA, United States.ORCID 0000-0003-2419-8536 James V LaceyBeckman Research Institute, City of Hope, Duarte, CA, United States.
Bernard A RosnerChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.ORCID 0000-0001-6907-0056 Yu-Hsiang ShuDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States.ORCID 0009-0007-0114-3950 Brenda M BirmannChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.ORCID 0000-0002-7550-5498 Chun R ChaoDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States.ORCID 0000-0002-6072-4954 Funding
VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9MTransgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3MStatistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ROSNER, BERNARD A · 2000 to 2019
$77.8MCALIFORNIA TEACHERS STUDYR01CA077398 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BERNSTEIN, LESLIE · 1998 to 2014
$29.7MLife Course Cancer Epidemiology Cohort in WomenU01CA176726 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI ELIASSEN, A. HEATHER, WILLETT, WALTER C. · 2018 to 2025
$22.4MLong Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3MOil and Gas as Drivers of Climate Change and Health: Developing unique resources to investigate multi-level and diverse effects of exposure to oil and gas wellsU01CA199277 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI LACEY, JAMES V, MARTINEZ, MARIA ELENA · 2015 to 2024
$20.7MTraining Program in Cancer EpidemiologyT32CA009001 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI A. Heather Eliassen, Meir Stampfer · 1985 to 2026
$17.3MCancer Epidemiology Cohort in Male Health ProfessionalsU01CA167552 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Lorelei Mucci, Walter C. Willett · 2017 to 2026
$17.0MCTSA K12 Program at Tufts UniversityK12TR004384 · NCATS · TUFTS UNIVERSITY BOSTON · PI Karen Freund, Lesley Ann Inker · 2023 to 2026
$6.1MRisk factors for molecular subtypes of NHL a prospective evaluationR01CA202712 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI BIRMANN, BRENDA M, WANG, SOPHIA S. · 2016 to 2020
$3.7MA prospective analysis of peripheral blood cytokines and non-Hodgkin lymphomaR01CA149445 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BIRMANN, BRENDA M · 2011 to 2015
$3.0MNational Institutes of Health grants P01 CA87969National Institutes of Health grants R01CA202712National Institutes of Health grants UM1CA1649170National Institutes of Health training grants 1K12TR004384National Institutes of Health training grants T32CA009001NCATS NIH HHS K12 TR004384NCCDPHP CDC HHS NU58DP006344NCI NIH HHS HHSN261201800009CNCI NIH HHS HHSN261201800009INCI NIH HHS HHSN261201800015CNCI NIH HHS HHSN261201800015INCI NIH HHS HHSN261201800032CNCI NIH HHS HHSN261201800032INCI NIH HHS P01 CA087969NCI NIH HHS P30 CA023100NCI NIH HHS P30 CA033572NCI NIH HHS R01 CA077398NCI NIH HHS R01 CA098122NCI NIH HHS R01 CA149445NCI NIH HHS R01 CA202712NCI NIH HHS R01 CA207020NCI NIH HHS T32 CA009001NCI NIH HHS U01 CA167552NCI NIH HHS U01 CA176726NCI NIH HHS U01 CA199277NCI NIH HHS UM1 CA186107United States Department of Agriculture 58-8050-3-003
6 · The paper itselfAbstract
backgroundPrior studies suggest positive associations of type 2 diabetes (T2D) with risk of non-Hodgkin lymphoma (NHL) and multiple myeloma (MM), but few studies had sufficient statistical power to evaluate associations for specific histological subtypes.
methodsWe pooled data from the Cancer Prevention Study-II Nutrition Cohort, California Teachers' Study, Health Professionals Follow-up Study, Nurses' Health Study (NHS), and NHSII cohorts and a sample of Kaiser Permanente Southern California members (585,114 total study participants). We confirmed incident diagnoses of NHL and MM using medical records or cancer registries. T2D history was assessed by self-report or clinical diagnosis. We estimated the associations of T2D history (yes/no) and T2D duration with risk of overall NHL, NHL subtypes, or MM using multivariable Cox regression models adjusted for age, sex, cohort, follow-up year, race, education, smoking, and body mass index.
resultsWe confirmed 11,478 NHL and 2,783 MM diagnoses over a median follow-up of 20 years. T2D history was not associated with overall NHL risk but was positively associated with risk of diffuse large B-cell lymphoma (DLBCL; hazard ratio [HR] = 1.15, 95% confidence interval [CI] = 1.04 to 1.28) and MM (HR = 1.20, 95% CI = 1.07 to 1.35) and inversely associated with risk of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (HR = 0.45, 95% CI = 0.27 to 0.75), T-cell NHL (HR = 0.78, 95% CI = 0.62 to 0.97), and mycosis fungoides/Sézary syndrome (HR = 0.67, 95% CI = 0.46 to 0.98). T2D duration was positively associated with risk of DLBCL and MM.
conclusionsOur findings suggest a role for T2D in DLBCL and MM; thus, T2D prevention may be important in reducing their incidence. Some unexpected inverse associations require further investigation.
Indexed as
Diabetes Mellitus, Type 2Lymphoma, Non-HodgkinMultiple MyelomaAdultAgedCaliforniaFemaleFollow-Up StudiesHumansIncidenceLymphoma, Large B-Cell, DiffuseLymphoma, T-CellMaleMiddle AgedMycosis FungoidesProportional Hazards Models
Identifiers
PMID41702379
PMCPMC13102175
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390